James Dentzer, Curis CEO

FDA lifts par­tial hold on Curis' lym­phoma study — shares spike

Four months af­ter the FDA put two clin­i­cal tri­als from Curis on clin­i­cal hold, the FDA is now ap­par­ent­ly con­tent with how the biotech will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.